Collection of data from patients with ANCA-associated vasculitis
Biocollection of Patients With ANCA Associated Vasculitis Diagnosed Within the CERAINO Autoimmune Disease Reference Center, Part of the Global BRAISE Project (B-dependent Rare AutoImmune DiseaSES
This study is collecting information and samples from people with ANCA-associated vasculitis to see if they can find out who is more likely to have a relapse and who might be able to stop their medications safely.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | University Hospital, Brest Academic / other |
| Locations | 1 site (Brest) |
| Trial ID | NCT05364892 on ClinicalTrials.gov |
What this trial studies
This study aims to collect standardized data from patients diagnosed with ANCA-associated vasculitis, a rare and severe autoimmune disease. By gathering blood, fecal, and urinary samples, along with patient questionnaires, the research seeks to identify predictors of disease relapse and other complications. The long-term goal is to improve patient management by determining which individuals are at higher risk for relapse and which can safely discontinue immunosuppressive treatments. This multi-year follow-up will enhance understanding of the disease's characteristics and its impact on patient prognosis.
Who should consider this trial
Good fit: Ideal candidates include adults diagnosed with ANCA-associated vasculitis who are being treated at the reference center for rare autoimmune diseases.
Not a fit: Patients who are minors, unable to consent, or have severe anemia (Hb < 7g/dL) may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better management strategies for patients with ANCA-associated vasculitis, reducing the risk of relapse and treatment side effects.
How similar studies have performed: While studies on ANCA-associated vasculitis exist, this approach of comprehensive data collection for predicting relapse is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major patients with no upper age limit. * Patients assessed as part of the reference centre for rare autoimmune diseases at the CHRU in Brest. * Patients for whom a diagnosis of ANCA-associated vasculitis is made by the physician in charge of the patient, according to the definitions of the Chapel-Hill Consensus Conference. * Patient affiliated with Social Security * Patient who has signed written informed consent Exclusion Criteria: * Minor * Patients unable to consent. * Patients refusing to participate in research * Patient under legal protection (tutelage, curatorship) * Pregnant or lactating women * Hemoglobin (Hb) \< 7g/dL
Where this trial is running
Brest
- CHRU de Brest - Service de rhumatologie — Brest, France (Recruiting)
Study contacts
- Study coordinator: Divi CORNEC
- Email: divi.cornec@chu-brest.fr
- Phone: (0)2 98 34 72 64
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.